Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Inflammatory Bowel Disease and Pancreatic Cancer Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for REG3A drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | REG3A ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View REG3A Products |
| Gene Delivery | REG3A Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View REG3A Products |
| Benchmark Ab | Anti-REG3A Recombinant positive control. |
View REG3A Products |
| Validator | REG3A siRNA Set For knockdown verification. |
View REG3A Products |
| Related Target A | REG1A Homolog counter-screening to ensure specificity. |
View REG1A Products |
| Related Target B | REG3G Homolog counter-screening to ensure specificity. |
View REG3G Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species cyno/mouse eval | Human/Mouse/Cyno ortholog proteins available with >95% purity |
| Subfamily counter screening | Homolog panel proteins (REG1A, REG3G) strictly verified by mass spec |
| Lack of Controls | Clinical Benchmark Antibodies included |
| False Positives | Validated siRNA included for specificity checks |
Live REG3A R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for REG3A therapeutics and diagnostics is intensifying, with major players shifting focus toward precise monoclonal antibodies for biomarker detection and neutralization. Characterized by its C-type lectin domain, REG3A plays a critical role in tissue regeneration and antimicrobial defense. As first-generation therapies reach the clinic, the next wave of R&D is targeting selective modulation in inflammatory bowel disease (IBD) and pancreatic cancer.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody | Biotech Innovators | IBD, Pancreatitis | Selectivity Assay (Need high-purity ECD) |
| Diagnostic Biomarker | Diagnostic Firms | Pancreatic Cancer | High-Affinity Binding (Need Sequence Verified Ag) |
| Recombinant Protein | Regenerative Med | Tissue Repair | Functional Assays (Endotoxin Controlled) |